DUBLIN, July 20, 2023 /PRNewswire/ -- The "REXULTI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
"This "REXULTI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REXULTI for schizophrenia in the seven major markets. A detailed picture of the REXULTI for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REXULTI for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REXULTI market forecast analysis for schizophrenia in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia. The inactive ingredients consist of lactulose monohydrate, cornstarch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, and colorants of titanium dioxide, iron oxide, and ferrous ferric oxide. Also, brexpiprazole is a round tablet with six strengths ranging from 0.25 mg to 4 mg. Dosage and Administration
The recommended starting dosage for REXULTI is 1 mg once daily on Days 1-4, orally with or without food. The recommended target REXULTI dosage is 2-4 mg once daily. The drug is titrated to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg. In-depth REXULTI Market Assessment
This report provides a detailed market assessment of REXULTI for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032. The report provides the clinical trials information of REXULTI for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates. A comprehensive product overview including the REXULTI description, mechanism of action, dosage and administration, research and development activities in schizophrenia. Elaborated details on REXULTI regulatory milestones and other development activities have been provided in this report. The report also highlights the REXULTI research and development activities in schizophrenia across the United States, Europe and Japan. The report also covers the patents information with expiry timeline around REXULTI. The report contains forecasted sales of for schizophrenia till 2032. Comprehensive coverage of the late-stage emerging therapies for schizophrenia. In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REXULTI dominance.
Other emerging products for schizophrenia are expected to give tough market competition to REXULTI and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REXULTI in schizophrenia. The in-depth analysis of the forecasted sales data of REXULTI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REXULTI in schizophrenia. 2.2. Clinical Development
2.2.2. Clinical trials information
2.2.3. Safety and Efficacy
2.3. Regulatory Milestones
2.4. Other Developmental Activities
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. REXULTI Market Assessment
5.3. Country-wise Market Analysis
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ukmbfx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets